Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 7/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579175 | 1.00 | EPAS1 (0.34) | EPAS1CSNK2A1L3MBTL1PDE4APDE4C | |
| SCHEMBL30150671 | 1.00 | EPAS1 (0.34) | EPAS1CSNK2A1L3MBTL1PDE4APDE4C | |
| SCHEMBL29206714 | 0.82 | CSNK2A1 (0.35) | EPAS1CSNK2A1ALPL | |
| SCHEMBL29959365 | 0.80 | CSNK2A1 (0.32) | CSNK2A1PDE4APDE4CPDE4D | |
| SCHEMBL23578707 | 0.80 | CSNK2A1 (0.32) | CSNK2A1PDE4APDE4CPDE4D | |
| SCHEMBL2185158 | 0.77 | PDE4A (0.34) | PDE4APDE4CPDE4DESR2CA1 | |
| SCHEMBL24819988 | 0.77 | L3MBTL1 (0.34) | CSNK2A1L3MBTL1 | |
| SCHEMBL23592754 | 0.74 | NQO1 (0.39) | CSNK2A1 | |
| SCHEMBL21313423 | 0.74 | PKM (0.43) | EPAS1L3MBTL1ESR2CA1CA2 | |
| SCHEMBL1396954 | 0.74 | PDE4A (0.36) | EPAS1L3MBTL1PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368616-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4495110-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-01-22 | — | — | EP | disclosed |
| CN-118871433-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-117940424-A | EGFR inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117916232-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117858872-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, EGFR, WEE2 | EPAS1 2594/4885CSNK2A1 1381/4885L3MBTL1 4742/4885 |
| US-20250368616-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | EPAS1 2252/4885CSNK2A1 2155/4885L3MBTL1 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.